摘要
目的探讨广泛期小细胞肺癌多学科综合治疗模式。方法回顾性分析我院广泛期小细胞肺癌患者治疗资料和随访结果。结果纳入分析的49例患者,男女比例为4.4:1,年龄平均61.47±9.738岁(38～83岁)。转移部位以肝脏、骨、颅内最多见,以化疗为主要治疗手段,辅以转移部位的局部治疗。有近1/3的患者接受了三线及以上治疗,每一线治疗中又有1/3～1/2的患者接受了放疗、伽马刀、X刀、动脉灌注等局部治疗。49例患者10例至今存活,36例死亡,3例失访。1年、2年及5年生存率为64%、35%和14%,其中局限期进展到广泛期患者和诊断时即为广泛期患者的中位生存期有统计学差异(22个月vs.12个月,P=0.016)。结论广泛期小细胞肺癌患者经多线化疗和综合治疗,耐受性良好,可能改善预后,局限期进展后进入广泛期患者治疗后生存优于起病即为广泛期患者。
Objective To explore the multi-disciplinary treatment of small-cell lung cancer with extensive stage. Methods We retrospectively analyze 49 cases admitted to our department during the last decade. Results Totally 49 cases [ M ： F 4. 4 ： 1, average age 61.47 ±9. 738 years （38-83years） ] were enrolled. The most common metastatic sites were liver, bone, and brain. Patients were mainly treated with chemotherapy, with local treamtment of radiotherapy, γ- knife, X-knife and transarterial chemothrapy. 1/3 patients were treated with at least third-line chemotherapy, and at each line treatment, 1/3 to 1/2 received additional local therapy. 19.2% to 28.9% of patients experienced 3 to 4 degree hematologic toxicity, less than 2. 5% had 3 to 4 degree gastrointestinal toxicity, and 2 suffured from herpus infection. Of 49 cases, 10 were still alive, 36 died, and 3 were lost during the follow-up. The 1-year, 2-year, and 5-year survival rates were 64% , 35% , and 14% , respectively. The median survival befween patients progressed from local stage and those initially diagnosed as extensive stage was significantly different （22m vs. 12m, P =0. 016）. Conclusion Patients with small-cell lung cancer with extensive stage will benefit from multi-disciplinary treatment, and patients with diseases progress from local stage have longer survivals.
出处
《癌症进展》
2011年第2期209-212,共4页
Oncology Progress
关键词
小细胞肺癌
广泛期
多学科
small-cell lung cancer extensive stage multi-disciplinary
